Prognosis of surgically determined complete responders in advanced ovarian cancer
- 1 March 1985
- Vol. 55 (5) , 1129-1135
- https://doi.org/10.1002/1097-0142(19850301)55:5<1129::aid-cncr2820550531>3.0.co;2-o
Abstract
From January 1971 through through December 1981, 246 patients with advanced (Stages III and IV) epithelial ovarian cancer underwent second-look laparotomy at The University of Texas M. D. Anderson Hospital and Tumor Institute at Houston. Eighty-five of these patients had a complete response (negative second-look laparotomy) following treatment with a variety of chemotherapeutic regimens. Three patients had also received irradiation. Patients were analyzed according to pretreatment characteristics (age, FIGO stage, ascites, pleural effusion, histologic grade, tumor type, type of surgery, residual tumor diameter, initial clinical status) and by the number of biopsy specimens taken at second-look laparotomy. The probability of recurrence and the length of survival following a negative second-look laparotomy are statistically related to these characteristics. Twenty of the 85 patients (24%) developed recurrent disease 5 to 32 months after laparotomy. The estimated 2- and 5-year survival rates are 99% and 85%, respectively. Patients who achieve a surgically determined complete response have an excellent chance for long-term survival.This publication has 23 references indexed in Scilit:
- A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancerGynecologic Oncology, 1983
- Role of “third-look” laparotomy in the guidance of ovarian cancer treatmentGynecologic Oncology, 1983
- Computerized tomography in ovarian cancerGynecologic Oncology, 1983
- Acute Nonlymphocytic Leukemia after Therapy with Alkylating Agents for Ovarian CancerNew England Journal of Medicine, 1982
- Second-look laparotomy for ovarian cancerGynecologic Oncology, 1981
- Can computed tomography substitute for second-look operation in ovarian carcinoma?Gynecologic Oncology, 1981
- Acute leukemia after chemotherapy (melphalan)Cancer, 1978
- Acute Leukemia after Alkylating-Agent Therapy of Ovarian CancerNew England Journal of Medicine, 1977
- Second trial drugs in ovarian cancerGynecologic Oncology, 1977
- Survival Curve for Cancer Patients Following TreatmentJournal of the American Statistical Association, 1952